Vancomycin PO

C. diff Risk


Oral Bioavailability


Approximate Cost

Spectrum Of Activity


No dosing adjustments required

No dosing adjustments required

125mg PO QID for 14 days.

Intra-colonic dose
250mg in 100mL of NS by rectal enema q6h

General Information

Common Usage

Only indication is in the therapy of C. difficile infection, particularly recurrent or severe disease

Drug Monitoring

Possibility of accumulation in severe renal dysfunction.

Additional Information

No oral absorption.

May increase vancomycin resistant Enterococci colonization in the gut.


Antimicrobial class: Glycopeptide

Pregnancy category: B

Average serum half life: 0 hours

Biliary penetration: None

CSF penetration: None

Lung penetration: None

Urine penetration: None